Teva is divesting Teva Takeda, its joint venture with Takeda Pharmaceutical in Japan, as it seeks to focus on bringing innovative medicines to the Japanese market.
Teva Divests Takeda JV, Pivots To Innovative Drugs In Japan
Takeda Expects $365m Payment
The divestment decision comes years after it slimmed down amid challenges in the Japanese generic market.
More from Strategy
More from Generics Bulletin
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
• By
Fresenius Kabi has met its end of the bargain to launch biosimilars to Prolia/Xgeva in the middle of this year, after bagging FDA approvals. The German firm is also set to hear back on its filings in Europe imminently.
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).